NextCure, Inc. (NASDAQ:NXTC) Shares Purchased by Logos Global Management LP

Logos Global Management LP lifted its position in NextCure, Inc. (NASDAQ:NXTC) by 29.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,500,000 shares of the company’s stock after purchasing an additional 575,000 shares during the period. Logos Global Management LP owned about 8.94% of NextCure worth $3,975,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in NXTC. Cable Car Capital LLC purchased a new stake in NextCure in the 4th quarter worth $702,000. Renaissance Technologies LLC grew its holdings in shares of NextCure by 15.4% during the second quarter. Renaissance Technologies LLC now owns 462,144 shares of the company’s stock worth $735,000 after buying an additional 61,744 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of NextCure by 9.3% during the first quarter. Vanguard Group Inc. now owns 987,324 shares of the company’s stock worth $2,202,000 after buying an additional 83,700 shares in the last quarter. Finally, Affinity Asset Advisors LLC purchased a new stake in shares of NextCure during the first quarter worth $3,031,000. 42.65% of the stock is currently owned by institutional investors and hedge funds.

NextCure Stock Performance

Shares of NXTC opened at $1.40 on Tuesday. The stock has a market capitalization of $39.16 million, a PE ratio of -0.61 and a beta of 0.79. NextCure, Inc. has a 1 year low of $0.98 and a 1 year high of $2.57. The company’s 50-day simple moving average is $1.54 and its 200-day simple moving average is $1.60.

NextCure (NASDAQ:NXTC) last issued its earnings results on Thursday, August 1st. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.19). On average, sell-side analysts predict that NextCure, Inc. will post -1.79 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on NXTC shares. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of NextCure in a report on Friday, May 31st. Needham & Company LLC reissued a “buy” rating and issued a $4.00 price objective on shares of NextCure in a report on Friday, August 2nd.

About NextCure

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.